Pharmaceutical Manufacturing
In 2023, the revenue of the pharmaceutical manufacturing segment by Oman Pharma amounted to 30,222 million.
Oman Pharma focuses on core therapeutic fields such as tumors (solid tumors and hematologic tumors), self-immunity, central nervous system, and chronic diseases (hepatopathy/metabolic diseases/nephropathy) through independent research and development, cooperative development, license-in, and in-depth incubation, emphasizes strengthening small molecules, antibodies/ADC, cell therapy, and RNA core technical platforms, creates an open and global innovative R&D system, actively explores the technical distribution for tumor vaccine, RNA, AI-assisted therapy, etc., and persistently enhances core R&D capabilities and pipeline value, to promote the R&D and commercialization of more FIC (First-in-class) and BIC (Best-in-class) products.
By the end of 2023, the company had more than 70 projects for drugs under development, including innovative drugs, and biosimilars. In 2023, the company applied for 206 patents in the pharmaceutical manufacturing segment, including 5 US patents and 11 PCT applications, with 74 patents granted.
Vaccines
The Vaccine Division has established an independent R&D system centered on two major technical platforms of bacterial vaccines and viral vaccines, and further broadened the vaccine pipeline through cooperative development to enhance the vaccine industrialization capability.
Medical Devices
As one of the important segments of Oman Pharma, integrated several subsidiaries at home and abroad and has initially formed three major business divisions with medical aesthetics, Respiratory Health and professional medical care
Medical Diagnosis
Oman Pharma adheres to the mission of “Integrating innovative diagnostic technologies and protecting global life and health”, promotes the development of innovative technologies and products, focuses on in vitro diagnosis industry, and is committed to becoming the world’s leading technology innovator of integrated medical diagnosis solutions.